Orcun Can

Acibadem, Turkey

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

PGR expression as a pharmacogenomic companion biomarker to GENE70-derived genomic risk in ER-positive/HER2-negative breast cancer.

PGR expression as a pharmacogenomic companion biomarker to GENE70-derived genomic risk in ER-positive/HER2-negative breast cancer.

Journal: Pakistan journal of pharmaceutical sciences

Published: September 08, 2026

Development of a biomarker-guided chemotherapy response model using combined CEA and CA19-9 profiles in esophageal cancer: A real-world pharmacotherapeutic study.

Development of a biomarker-guided chemotherapy response model using combined CEA and CA19-9 profiles in esophageal cancer: A real-world pharmacotherapeutic study.

Journal: Pakistan journal of pharmaceutical sciences

Published: September 08, 2026

Neoadjuvant nivolumab plus chemotherapy in resectable NSCLC: A pharmacological outcome study.

Neoadjuvant nivolumab plus chemotherapy in resectable NSCLC: A pharmacological outcome study.

Journal: Pakistan journal of pharmaceutical sciences

Published: June 09, 2026

Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study.

Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study.

Journal: Cancers

Published: May 12, 2026

Evolving Concepts and Contemporary Management of Early-Stage Breast Cancer: An Evidence-Based Approach to Grey Zones from a Comprehensive Breast Unit Part 2: Systemic Treatment.

Evolving Concepts and Contemporary Management of Early-Stage Breast Cancer: An Evidence-Based Approach to Grey Zones from a Comprehensive Breast Unit Part 2: Systemic Treatment.

Journal: European journal of breast health

Published: December 25, 2025

Lorlatinib-Induced Blindness: A Rare Entity.

Lorlatinib-Induced Blindness: A Rare Entity.

Journal: Practical radiation oncology

Published: October 23, 2024

Real-Life Experience with Entrectinib in Neurotrophic Tyrosine Receptor Kinase Fusion-Positive Solid Tumors: A Multicenter Retrospective Trial.

Real-Life Experience with Entrectinib in Neurotrophic Tyrosine Receptor Kinase Fusion-Positive Solid Tumors: A Multicenter Retrospective Trial.

Journal: Targeted oncology

Published: August 28, 2024

Neoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Nationwide Retrospective Turkish Oncology Group Study.

Neoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Nationwide Retrospective Turkish Oncology Group Study.

Journal: Cancers

Published: August 19, 2024

How reliable is the high-volume definition in prostate cancer patients: the potential game-changing role of PSMA.

How reliable is the high-volume definition in prostate cancer patients: the potential game-changing role of PSMA.

Journal: Nuclear medicine communications

Published: June 19, 2023

Atezolizumab Lung Toxicity: Importance of Combination Treatment On The Edge of Life, A Case Report.

Atezolizumab Lung Toxicity: Importance of Combination Treatment On The Edge of Life, A Case Report.

Journal: Current drug safety

Published: February 11, 2023

Clinical Features and Prognostic Factors of Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multicenter Study from the Turkish Oncology Group Kidney Cancer Consortium.

Clinical Features and Prognostic Factors of Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multicenter Study from the Turkish Oncology Group Kidney Cancer Consortium.

Journal: Urologia internationalis

Published: May 24, 2022

External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.

External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.

Journal: Clinical genitourinary cancer

Published: April 18, 2022

Showing 1-12 of 25

Last Updated: 09/26/2026